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Metoprolol Comparison in Hypertensives) study in diabetic hy-
pertensives showed maintained glycemic control and improved
insulin resistance with carvedilol versus metoprolol (8). Similarly,
nebivolol demonstrated improved insulin sensitivity when com-
pared with metoprolol in hypertensive patients (9).
The authors incorrectly state that the European Society for
Hypertension/European Society of Cardiology (ESH/ESC) is
no longer endorsing beta-blockers as first-line therapy for
hypertension. In actuality, ESH/ESC guidelines, published this
year, maintain beta-blockers among the classes of drugs suitable
for initiation and maintenance of blood pressure treatment (10).
Furthermore, ESH/ESC and the American College of Clinical
Endocrinologists recognize the differences that exist between
agents in this class, distinguishing the vasodilatory beta-
blockers from traditional ones in patients with metabolic risk
factors.
We are not sure what the phenotype of an “uncomplicated”
patient with hypertension is. Clearly, many with increased blood
pressures have non-obstructive coronary and carotid plaques.
The use of beta-blockers in the treatment of patients with
hypertension is deeply rooted in the knowledge of the role of the
sympathetic nervous system in the pathophysiology of complica-
tions. We believe that recommendations for the use of beta-
blockers in an individual with hypertension should be made after
reviewing the totality of the data. Beta-blockers will continue to
play a critical role in treatment of hypertension, and dismissing the
entire class without fully examining the evidence might indeed
amount to “throwing the baby out with the bath water.”
Thomas D. Giles, MD*
George L. Bakris
Michael A. Weber





Please note: The authors are consultants and speak for the following pharmaceutical
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Reply
We thank Dr. Giles and colleagues for their interest in our paper
(1) and completely agree with their contention that “recommen-
dations for the use of beta-blockers in the individual with hyper-
tension should be made after reviewing the totality of the data.”
Unfortunately, the totality in this case is completely negative. Ever
since our meta-analysis about a decade ago, study after study has
attested to the inefficacy of beta-blockers in hypertension. Why
would any physician expose a hypertensive patient to a drug that
reduces mortality no better than placebo, as evidenced in the
thorough Cochrane meta-analysis (2), and yet leads to a with-
drawal rate that is twice as high as the one seen with diuretics
(which are certainly not the best-tolerated drug class for the
treatment of hypertension)? We are puzzled by our colleagues’
cherrypicking of the STOP-1 and -2 (Swedish Trial in Old
Patients with Hypertension-1 and -2). Neither of those studies
dared to conclude that beta-blockers per se reduce morbidity and
mortality. The reason for this is very simply that neither one
analyzed the effects of diuretics and beta-blockers separately. Thus,
STOP-1 and -2 studies are classical examples of gin-and-tonic
studies in which about two-thirds of patients treated with a
beta-blocker also received a thiazide diuretic.
The INVEST (International Verapamil-Trandolapril Study) is
a landmark trial in which an atenolol (given mostly twice a
day)-based regimen was compared with a verapamil-based regi-
men, as Dr. Giles and colleagues point out. However, all of the
patients in the INVEST study had well defined coronary artery
disease, and an extrapolation from such a high-risk population to
uncomplicated hypertension is not appropriate. As can be seen in
our Figure 3 (1) we are convinced that coronary artery disease is an
acceptable indication for the use of beta-blockers.
We use the term pseudoantihypertensive efficacy to describe the
observation in the CAFE (Conduit Artery Function Evaluation)
study (3) that, for a given brachial blood pressure, atenolol lowered
central aortic blood pressure significantly less than did amlodipine.
Therefore, practicing physicians may wrongly conclude that the
patient has well controlled hypertension when central aortic
pressure is still significantly elevated. The term pseudoantihyper-
tensive efficacy aptly describes this phenomenon.
We certainly agree with our colleagues, and we have stated so
(4), that vasodilating beta-blockers have a different hemodynamic
profile and a different metabolic/endocrine profile, induce less
weight gain (5), and are better tolerated than the traditional
beta-blockers. Thus, nebivolol and carvedilol are not only better
tolerated but also have the potential to be more beneficial in terms
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of morbidity and mortality reduction than traditional beta-
blockers. However, this potential remains hypothetic as long as we
have no conclusive outcome studies attesting to this. If indeed the
companies manufacturing these drugs are concerned about this
issue they should mount outcome studies in hypertension. This
does not need to be an exceedingly expensive endeavour, as is
evidenced by the fact that it only took 1,473 patients with
cerebrovascular disease to show that stroke reduction was no better
with atenolol than with placebo (6).
We agree that many patients with increased blood pressure have
some degree of nonobstructive coronary disease. However, neither
our nor the Cochrane meta-analysis showed any efficacy of
beta-blockers for primary prevention of coronary disease. The
Cochrane meta-analysis specifically stated that “the absence of an
effect on heart disease [compared with] placebo or no treatment”
led to the conclusion that beta-blockers should not be used as
first-line drugs in the treatment of hypertension.
We are not particularly concerned about “throwing out the baby
with the bathwater.” In 2006 more than 100 million prescriptions
for beta-blockers were written in the U.S. Atenolol remains the
fourth most prescribed drug, and most of these prescriptions are
for atenolol given once a day for the treatment of hypertension.
This is a sad state of the art, given the fact that atenolol has never
shown to reduce morbidity and mortality in hypertension. One
may also want to consider that treatment of 1,000 patients with
beta-blockers for 4.4 years will result in 14 extra cases of diabetes,
3 extra deaths, and 5 extra strokes (7). This means that in the U.S.
alone, beta-blocker therapy may account for 70,000 new cases of
diabetes, 15,000 deaths, and 25,000 strokes every year.
Thus, many more gallons of bathwater can be thrown out before
the baby runs any risk of being harmed.
*Franz H. Messerli, MD, FACC, FACP
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